Neurometabolism of active neuropsychiatric lupus determined with proton MR spectroscopy

American Journal of Neuroradiology

Volumn 18, Issue 7, 1997, Pages 1271-1277

  Sibbitt Jr , Wilmer L ^a   Haseler, Luke J ^a   Griffey, Richard R ^a   Friedman, Seth D ^a   Brooks, William M ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Lupus erythematosus; Magnetic resonance; Spectroscopy

Indexed keywords

ADULT; BRAIN ISCHEMIA; BRAIN METABOLISM; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; HUMAN; MACROMOLECULE; MAJOR CLINICAL STUDY; NEUROPSYCHIATRY; PROTON NUCLEAR MAGNETIC RESONANCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ASPARTIC ACID; BRAIN; BRAIN DAMAGE, CHRONIC; BRAIN ISCHEMIA; BRAIN MAPPING; CHOLINE; CREATINE; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; ENERGY METABOLISM; FEMALE; HUMANS; LACTIC ACID; LIPID METABOLISM; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEURONS; REFERENCE VALUES;

EID: 20644437749     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus: a clinical-pathological study of 24 cases and review of the literature. Medicine 1968;47:337-369
2. Ellis SG, Verity MA. Central nervous systemic involvement in systemic lupus erythematosus: a review of neuropathological findings in 57 cases, 1955-1957. Semin Arthritis Rheum 1979;8: 212-221
3. Bluestein HG. The central nervous system in systemic lupus erythematosus. In: Lahita RG, ed. Systemic Lupus Erythematosus. 2nd ed. New York, MY: Churchill Livingstone; 1992:639-655
4. West SG. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994;20:129-158
5. Carbotte RM, Denburg SD, Denburg JA. Cognitive dysfunction and systemic lupus erythematosus. In: Lahita RG, ed. Systemic Lupus Erythematosus. New York, NY: Churchill Livingstone; 1992:865-881
6. Denburg S, Carbotte RM, Denburg JA. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum 1994;37:1311-1320
7. Adelman DC, Saltiel E, Klinenberg JR. The neuropsychiatric manifestations of systemic lupus erythematosus: an overview. Semin Arthritis Rheum 1986;15:185-193
8. Bluestein HG. Nervous system in systemic lupus erythematosus. Immunol Allergy Clin North Am 1988;8:315-323
9. Burnstein SL, Janoff L, McCormick K. Neuropsychiatric involvement in systemic lupus erythematosus: case report and review of the literature. J Am Osteopath Assoc 1987;87:626-631
10. Gibson T, Myers AR. Nervous system involvement in systemic lupus erythematosus. Ann Rheum Dis 1976;35:398-406
11. Ginzler EM, Schorn K. Outcome and prognosis in systemic lupus erythematosus. Rheum Dis Clin North Am 1988;14:67-78
12. van Dam AP. Diagnosis and pathogenesis of CNS lupus. Rheumatol Int 1991;11:1-11
13. McCune WJ, MacGuire A, Aisen A, Gebarski S. Identification of brain lesions in neuropsychiatric systemic lupus erythematosus by magnetic resonance scanning. Arthritis Rheum 1988;31:159-166
14. Sibbitt WL Jr, Sibbitt RR. Magnetic resonance spectroscopy and positron emission tomography scanning in neuropsychiatric systemic lupus erythematosus. Rheum Dis Clin North Am 1993;19: 851-868
15. Sibbitt WL Jr, Haseler LH, Griffey RH, Hart BL, Sibbitt RR, Matwiyoff NA. Analysis of cerebral structural changes in systemic lupus erythematosus by proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol 1994;45:923-928
16. Sibbitt WL Jr, Brooks WM, Haseler LJ, et al. Spin-spin relaxation of brain tissues in systemic lupus erythematosus. Arthritis Rheum 1995;38:810-818
17. Tan EM, Cohen AS, Fries JF, et al. 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-1277
18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-640
19. Hawker G, Gabriel S, Bombardier C, Goldsmith C, Caron D, Gladman D. A reliability study of SLEDA1: a disease activity index for systemic lupus erythematosus. J Rheumatol 1993;20:657-660
20. Carbotte RM, Denburg JA. Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis 1986;174:357-364
21. Denburg JA, Carbotte RM, Denburg SD. Neuronal antibodies and cognitive dysfunction in systemic lupus erythematosus. Neurology 1987;37:464-467
22. Griffey RH, Flamig DP. VAPOR for solvent-suppressed, short echo, volume localized proton spectroscopy. J Magn Reson 1990; 88:161-166
23. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N YAcad Sci 1987;508:333-348
24. 1NMR spectra of metabolites in the human brain. Proc Natl Acad Sci U S A 1988;85:1821-1825
25. van Zijl P, Moonen CT, Alger JR, Cohen J, Chesnick SA. High field localized proton spectroscopy in small volumes: greatly improved localized and shimming using shielded strong gradients. Magn Reson Med 1989;10:256-265
26. Luyten PR, den Hollander JA. Observation of metabolites in the human brain by MR spectroscopy. Radiology 1986;161:795-798
27. Koller KJ, Zaczek R, Coyle JT. N-acetyl-aspartyl-glutamate: region levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J Neurochem 1984;43:1136-1142
28. Michaelis T, Merboldt K-D, Haenicke W, Gyngell ML, Bruhn H, Frahm J. On the identification of cerebral metabolites in localized 1-H NMR spectra of human brain in vivo. NMR Biomed 1991;4: 90-98
29. Urenjak J, Williams SR, Gadian DG, Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors and immature oligodendrocytes in vitro. J Neurochem 1992;59:55-61
30. Barker PB, Breiter SN, Soher BJ, et al. Quantitative proton spectroscopy of canine brain: in vivo and in vitro correlations. Magn Reson Med 1994;32:157-163
31. Meyerhoff DJ, MacKay S, Poole N, Dillon WP, Weiner MW, Fein G. N-acetylaspartate reductions measured by 1H MRS in cognitively impaired HIV-seropositive individuals. Magn Reson Imaging 1994;12:653-659
32. Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 1994;32:110-115
33. Sappey-Marinier D, Calabrese G, Hetherington HP, et al. Proton magnetic resonance spectroscopy of human brain: application to normal white matter, chronic infarction, and MRI white matter signal hyperintensities. Magn Reson Med 1992;26:313-327
34. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49-58
35. Olson JE, Katz-Stein A, Reo NV, Jolesz FA. Evaluation of acute brain edema using quantitative magnetic resonance imaging: effects of pretreatment with dexamethasone. Magn Reson Med 1992:24:64-74
36. Shiino A, Matsuda M, Morikawa S, et al. Proton magnetic resonance spectroscopy with dementia. Surg Neurol 1993;39:143-147
37. Ford CC, Griffey RH, Matwiyoff NA, Rosenberg GA. Multivoxel IH-MRS of stroke. Neurology 1992;42:1408-1412
38. Narayana PA, Wolinsky JS, Jackson EF, et al. Proton MR spectroscopy of gadolinium-enhanced multiple sclerosis plaques. J Magn Reson Imaging 1992;2:263-270
39. Sharma R, Venkatasubramanian PN, Barany M, Davis JM. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophr Res 1992;8:43-49
40. de Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995; 34:721-727
41. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD. Alzheimer disease: depiction of increased cerebral myoinositol with proton MR spectroscopy. Radiology 1993;187:433-437
42. Crockard HA, Gadian DG, Frackowiak RS, et al. Acute cerebral ischemia: concurrent changes in cerebral blood flow, energy metabolism, pH, and lactate measured with hydrogen clearance and 31P and 1H nuclear magnetic resonance spectroscopy, II: changes during ischemia. J Cereb Blood Flow Metab 1987;7:394-402
43. Mathews VP, Barker PB, Blackband SJ, Chatham JC, Bryan RN. Cerebral metabolites in patients with acute and subacute strokes: concentrations determined by quantitative proton MR spectroscopy. AJR Am J Roentgenol 1995;165:633-638
44. Fields RA, Sibbitt WL, Toubbeh H, Bankhurst AD. Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolopin antibodies. Ann Rheum Dis 1990;49:114-117
45. Hanly JG, Walsh NMG, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol 1992;19:732-741
46. Pinching AJ, Travers RL, Hughes GR, Jones T, Moss S. Oxygen-15 brain scanning for detection of cerebral involvement in systemic lupus erythematosus. Lancet 1978;1:898-900
47. Meyer GJ, Schober O, Stoppe G, Wildhagen K, Seidel JW. Hundeshagen H. Cerebral involvement in systemic lupus erythematosus (SLE): comparison of positron emission tomography (PET) with other imaging methods. Psychiatry Res 1989;29:367-368
48. Barker PB, Gillard JH, van Zijl PCM, et al. Acute stroke: evaluation with serial proton magnetic resonance spectroscopic imaging. Radiology 1992;192:723-732
49. Petroff OAC, Graham GD, Blamire AM, et al. Spectroscopic imaging of stroke in humans: histopathology correlates of spectral changes. Neurology 1992;42:1349-1359